Report Detail
Global Diabetic Macular Edema Drug Market Insights, Forecast to 2025
- RnM2716560 |
- 04 June, 2019 |
- Global |
- 112 Pages |
- QYResearch |
- Pharma & Healthcare
Diabetic Macular Edema (DME) is a leading cause of blindness among the working age population in most developed countries. DME is one of the major complications of diabetes and DME patients utilise significantly higher healthcare resources than non-DME diabetic patients.
Western Europe is expected to be the most lucrative market for diabetic macular edema, with market attractiveness index of 2.7.
The global Diabetic Macular Edema Drug market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Diabetic Macular Edema Drug market based on company, product type, end user and key regions.
This report studies the global market size of Diabetic Macular Edema Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Diabetic Macular Edema Drug in these regions.
This research report categorizes the global Diabetic Macular Edema Drug market by top players/brands, region, type and end user. This report also studies the global Diabetic Macular Edema Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Novartis
Bayer
Allergan
Hoffman-La Roche
Alimera
Valeant
Market size by Product
Intravitreal Injections
Intravitreal Implants
Market size by End User
Anti-VEGF
Corticosteroids
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Diabetic Macular Edema Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Diabetic Macular Edema Drug market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Diabetic Macular Edema Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Diabetic Macular Edema Drug submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Diabetic Macular Edema Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Diabetic Macular Edema Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Diabetic Macular Edema Drug Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Diabetic Macular Edema Drug Market Size Growth Rate by Product
- 1.4.2 Intravitreal Injections
- 1.4.3 Intravitreal Implants
- 1.5 Market by End User
- 1.5.1 Global Diabetic Macular Edema Drug Market Size Growth Rate by End User
- 1.5.2 Anti-VEGF
- 1.5.3 Corticosteroids
- 1.5.4 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Diabetic Macular Edema Drug Market Size
- 2.1.1 Global Diabetic Macular Edema Drug Revenue 2014-2025
- 2.1.2 Global Diabetic Macular Edema Drug Sales 2014-2025
- 2.2 Diabetic Macular Edema Drug Growth Rate by Regions
- 2.2.1 Global Diabetic Macular Edema Drug Sales by Regions
- 2.2.2 Global Diabetic Macular Edema Drug Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Diabetic Macular Edema Drug Sales by Manufacturers
- 3.1.1 Diabetic Macular Edema Drug Sales by Manufacturers
- 3.1.2 Diabetic Macular Edema Drug Sales Market Share by Manufacturers
- 3.1.3 Global Diabetic Macular Edema Drug Market Concentration Ratio (CR5 and HHI)
- 3.2 Diabetic Macular Edema Drug Revenue by Manufacturers
- 3.2.1 Diabetic Macular Edema Drug Revenue by Manufacturers (2014-2019)
- 3.2.2 Diabetic Macular Edema Drug Revenue Share by Manufacturers (2014-2019)
- 3.3 Diabetic Macular Edema Drug Price by Manufacturers
- 3.4 Diabetic Macular Edema Drug Manufacturing Base Distribution, Product Types
- 3.4.1 Diabetic Macular Edema Drug Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Diabetic Macular Edema Drug Product Type
- 3.4.3 Date of International Manufacturers Enter into Diabetic Macular Edema Drug Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Diabetic Macular Edema Drug Sales by Product
- 4.2 Global Diabetic Macular Edema Drug Revenue by Product
- 4.3 Diabetic Macular Edema Drug Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Diabetic Macular Edema Drug Breakdown Data by End User
6 North America
- 6.1 North America Diabetic Macular Edema Drug by Countries
- 6.1.1 North America Diabetic Macular Edema Drug Sales by Countries
- 6.1.2 North America Diabetic Macular Edema Drug Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Diabetic Macular Edema Drug by Product
- 6.3 North America Diabetic Macular Edema Drug by End User
7 Europe
- 7.1 Europe Diabetic Macular Edema Drug by Countries
- 7.1.1 Europe Diabetic Macular Edema Drug Sales by Countries
- 7.1.2 Europe Diabetic Macular Edema Drug Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Diabetic Macular Edema Drug by Product
- 7.3 Europe Diabetic Macular Edema Drug by End User
8 Asia Pacific
- 8.1 Asia Pacific Diabetic Macular Edema Drug by Countries
- 8.1.1 Asia Pacific Diabetic Macular Edema Drug Sales by Countries
- 8.1.2 Asia Pacific Diabetic Macular Edema Drug Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Diabetic Macular Edema Drug by Product
- 8.3 Asia Pacific Diabetic Macular Edema Drug by End User
9 Central & South America
- 9.1 Central & South America Diabetic Macular Edema Drug by Countries
- 9.1.1 Central & South America Diabetic Macular Edema Drug Sales by Countries
- 9.1.2 Central & South America Diabetic Macular Edema Drug Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Diabetic Macular Edema Drug by Product
- 9.3 Central & South America Diabetic Macular Edema Drug by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Diabetic Macular Edema Drug by Countries
- 10.1.1 Middle East and Africa Diabetic Macular Edema Drug Sales by Countries
- 10.1.2 Middle East and Africa Diabetic Macular Edema Drug Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Diabetic Macular Edema Drug by Product
- 10.3 Middle East and Africa Diabetic Macular Edema Drug by End User
11 Company Profiles
- 11.1 Novartis
- 11.1.1 Novartis Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Novartis Diabetic Macular Edema Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Novartis Diabetic Macular Edema Drug Products Offered
- 11.1.5 Novartis Recent Development
- 11.2 Bayer
- 11.2.1 Bayer Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Bayer Diabetic Macular Edema Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Bayer Diabetic Macular Edema Drug Products Offered
- 11.2.5 Bayer Recent Development
- 11.3 Allergan
- 11.3.1 Allergan Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Allergan Diabetic Macular Edema Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Allergan Diabetic Macular Edema Drug Products Offered
- 11.3.5 Allergan Recent Development
- 11.4 Hoffman-La Roche
- 11.4.1 Hoffman-La Roche Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Hoffman-La Roche Diabetic Macular Edema Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Hoffman-La Roche Diabetic Macular Edema Drug Products Offered
- 11.4.5 Hoffman-La Roche Recent Development
- 11.5 Alimera
- 11.5.1 Alimera Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Alimera Diabetic Macular Edema Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Alimera Diabetic Macular Edema Drug Products Offered
- 11.5.5 Alimera Recent Development
- 11.6 Valeant
- 11.6.1 Valeant Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Valeant Diabetic Macular Edema Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Valeant Diabetic Macular Edema Drug Products Offered
- 11.6.5 Valeant Recent Development
12 Future Forecast
- 12.1 Diabetic Macular Edema Drug Market Forecast by Regions
- 12.1.1 Global Diabetic Macular Edema Drug Sales Forecast by Regions 2019-2025
- 12.1.2 Global Diabetic Macular Edema Drug Revenue Forecast by Regions 2019-2025
- 12.2 Diabetic Macular Edema Drug Market Forecast by Product
- 12.2.1 Global Diabetic Macular Edema Drug Sales Forecast by Product 2019-2025
- 12.2.2 Global Diabetic Macular Edema Drug Revenue Forecast by Product 2019-2025
- 12.3 Diabetic Macular Edema Drug Market Forecast by End User
- 12.4 North America Diabetic Macular Edema Drug Forecast
- 12.5 Europe Diabetic Macular Edema Drug Forecast
- 12.6 Asia Pacific Diabetic Macular Edema Drug Forecast
- 12.7 Central & South America Diabetic Macular Edema Drug Forecast
- 12.8 Middle East and Africa Diabetic Macular Edema Drug Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Diabetic Macular Edema Drug Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Diabetic Macular Edema Drug . Industry analysis & Market Report on Diabetic Macular Edema Drug is a syndicated market report, published as Global Diabetic Macular Edema Drug Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Diabetic Macular Edema Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
